Takeda Pharmaceutical Co may consider making a move into generics in the emerging markets but not in Japan, according to remarks made by its president and reported by Reuters.
Yasuchika Hasegawa, who was making a speech about the country’s corporate management practices at the Foreign Correspondents’ Club of Japan in Tokyo, told reporters that “to get the entrance ticket for emerging countries, we might acquire the company who has a significant generic presence in those targeted areas,” Reuters reports that he singled out South America as a region Takeda may be interested in but did not elaborate on specific areas or companies.
However Mr Hasegawa said Takeda was not interested in getting into the Japanese generic drug market. This targeting of the emerging markets mirrors an approach being looked at by fellow Japanese firm Eisai, whose chief executive, Haruo Naito, told PharmaTimes World News earlier this year that the firm is interested in branded generics to cater specifically for the middle-income class of China and India.
Japan’s Daiichi Sankyo also sees collaborations with countries in emerging markets as a useful tool, having purchased a controlling stake in India’s Ranbaxy Laboratories a year ago.
